ST2, PIVKA-II, CEA, CA125 and their combinations in elderly liver metastases cancers: Development of a diagnostic scoring model

Table 2 Univariate analysis of liver metastasis in the construct group, n (%)

Variable	Liver metastasis group (n = 84)	Liver metastasis-free group (n = 252)	χ2/t	P value
Age (years), mean ± SD	67.94 ± 8.51	68.07 ± 8.44	0.055	0.956
Gender			0.162	0.687
Male	50 (59.52)	144 (57.14)
Female	34 (40.48)	108 (42.86)
Blood type			0.380	0.944
A	23 (27.38)	63 (25.00)
B	18 (21.43)	66 (26.19)
O	21 (25.00)	60 (23.81)
AB	22 (26.19)	63 (25.00)
Diet			0.726	0.394
Low-fat and low-cholesterol	47 (55.95)	131 (51.98)
High fat and high cholesterol	37 (44.05)	121 (48.02)
Nature of work			0.481	0.488
Brainpower	34 (40.48)	89 (35.32)
Physical strength	50 (59.52)	163 (64.68)
Course of illness (months)			3.505	0.061
< 3	39 (46.43)	131 (51.98)
≥ 6	45 (53.57)	121 (48.02)
BMI (kg/m2)			0.407	0.524
20-25	59 (70.24)	184 (73.02)
≥ 25	25 (29.76)	68 (26.98)
Installments			0.632	0.427
Phase I-II	40 (47.62)	128 (50.79)
Phase III	44 (52.38)	124 (49.21)
History of hepatitis B			0.258	0.611
Have	23 (27.38)	60 (23.81)
None	61 (72.62)	192 (76.19)
ST2 (pg/mL)	396.45 (332.18, 472.15)	49.87 (42.15, 58.64)	85.077	< 0.001
PIVKA-II (mAU/mL)	752.18 (682.34, 830.47)	28.92 (20.15, 38.74)	160.464	< 0.001
CEA (ng/mL)	320.45 (305.80, 337.22)	3.52 (2.65, 4.41)	325.563	< 0.001
CA125 (U/mL)	105.67 (92.14, 128.35)	25.08 (19.87, 31.65)	63.921	< 0.001
Fatty liver			84.183	< 0.001
Have	40 (47.62)	20 (7.94)
None	44 (52.38)	232 (92.06)

BMI: Body mass index; ST2: Soluble growth-stimulating gene 2; PIVKA-II: Protein induced by vitamin K absence or antagonist-II; CEA: Carcinoembryonic antigen; CA125: Carbohydrate antigen 125.